Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kezar Life Sciences to Participate in Three Upcoming Investor Conferences By: Kezar Life Science via Business Wire September 01, 2022 at 07:00 AM EDT Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, September 8, 2022, at 1:20 PM ET Format: Fireside Chat Event: H.C. Wainwright 24th Annual Global Investment Conference Location: New York, NY Date/Time: Tuesday, September 13, 2022, at 11:30 AM ET Format: Podium Presentation Event: Morgan Stanley 20th Annual Global Healthcare Conference Location: New York, NY Date/Time: Wednesday, September 14, 2022, at 9:10 AM ET Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005005/en/Contacts Investor Contact Gitanjali Jain Vice President, Investor Relations and External Affairs 650-269-7523 gjain@kezarbio.com Media Contact Liza Sullivan Argot Partners 212-600-1902 kezar@argotpartners.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences By: Kezar Life Science via Business Wire September 01, 2022 at 07:00 AM EDT Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, September 8, 2022, at 1:20 PM ET Format: Fireside Chat Event: H.C. Wainwright 24th Annual Global Investment Conference Location: New York, NY Date/Time: Tuesday, September 13, 2022, at 11:30 AM ET Format: Podium Presentation Event: Morgan Stanley 20th Annual Global Healthcare Conference Location: New York, NY Date/Time: Wednesday, September 14, 2022, at 9:10 AM ET Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005005/en/Contacts Investor Contact Gitanjali Jain Vice President, Investor Relations and External Affairs 650-269-7523 gjain@kezarbio.com Media Contact Liza Sullivan Argot Partners 212-600-1902 kezar@argotpartners.com
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, September 8, 2022, at 1:20 PM ET Format: Fireside Chat Event: H.C. Wainwright 24th Annual Global Investment Conference Location: New York, NY Date/Time: Tuesday, September 13, 2022, at 11:30 AM ET Format: Podium Presentation Event: Morgan Stanley 20th Annual Global Healthcare Conference Location: New York, NY Date/Time: Wednesday, September 14, 2022, at 9:10 AM ET Format: Fireside Chat Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005005/en/
Investor Contact Gitanjali Jain Vice President, Investor Relations and External Affairs 650-269-7523 gjain@kezarbio.com Media Contact Liza Sullivan Argot Partners 212-600-1902 kezar@argotpartners.com